Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis

• Main Authors: Begoña Porteiro (Author), Marcos F. Fondevila (Author), Xabier Buque (Author), Maria J. Gonzalez-Rellan (Author), Uxia Fernandez (Author), Alfonso Mora (Author), Daniel Beiroa (Author), Ana Senra (Author), Rosalia Gallego (Author), Johan Fernø (Author), Miguel López (Author), Guadalupe Sabio (Author), Carlos Dieguez (Author), Patricia Aspichueta (Author), Rubén Nogueiras (Author)
• Format: Book
• Published: Elsevier, 2018-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Recent reports have implicated the p53 tumor suppressor in the regulation of lipid metabolism. We hypothesized that the pharmacological activation of p53 with low-dose doxorubicin, which is widely used to treat several types of cancer, may have beneficial effects on nonalcoholic fatty liv...